Christopher Vendryes
Pain Medicine · Miami Shores, FLNPI 1205986916
Payments from drug & device makers
Across 226 payments — averaging $25.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Forte Bio-pharma LLC$682
- Collegium Pharmaceutical, Inc.$453
- Scilex Pharmaceuticals Inc.$445
- Medtronic$391
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$359
- plus $1K from 22 others
What the payments were for
- Travel & lodging$160%
- Food & beverage$5,788100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 101 | $2,402 |
| Forte Bio-pharma LLC | 3 | $682 |
| Collegium Pharmaceutical, Inc. | 20 | $453 |
| Scilex Pharmaceuticals Inc. | 24 | $445 |
| Medtronic | 8 | $391 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 26 | $359 |
| Boston Scientific | 3 | $140 |
| Pacira Pharmaceuticals Incorporated | 1 | $122 |
| Redhill Biopharma Inc. | 5 | $106 |
| Sentynl Therapeutics, Inc. | 6 | $86 |
| Nevro Corp. | 4 | $83 |
| Neotract Inc. | 1 | $77 |
| Nalu Medical, Inc. | 2 | $61 |
| Daiichi Sankyo Inc. | 3 | $59 |
| Johnson & Johnson | 3 | $57 |
| Urovant Sciences Inc | 2 | $45 |
| Virtus Pharmaceuticals LLC | 2 | $39 |
| Biodelivery Sciences International, Inc. | 2 | $29 |
| Sumitomo Pharma America, Inc. | 1 | $28 |
| Protega Pharmaceutials Inc | 1 | $21 |
| Vertos Medical, Inc. | 1 | $20 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
| Intercept Pharmaceuticals, Inc. | 1 | $16 |
| West Therapeutics Development, LLC | 1 | $15 |
| Orexo US, Inc. | 1 | $14 |
| AbbVie | 1 | $13 |
| Amgen | 1 | $12 |
| AstraZeneca | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,804 in reported general payments places this provider in the 65th percentile of 596 pain medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 20 | $16,096 |
| GemtesaVibegron | 18 | $15,343 |
| Tamsulosin Hcl | 132 | $985 |
| Solifenacin Succinate | 17 | $383 |
| Finasteride | 46 | $368 |
| Dutasteride | 15 | $255 |
| Oxybutynin Chloride | 15 | $60 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $28 | $15,34318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 596 pain medicine providers in Florida.
Other pain medicine in Miami Shores
- Anand PatelOrmond Beach$20.4M
- Julio PaezClermont$2.3M
- Joseph PergolizziNaples$2.1M
- Abel MurilloMiami$1.6M
- George MonluxPalm Coast$1.3M
- Ferdinand FormosoJacksonville$1M
- Cesar LassalleOrlando$1M
- Robert GuirguisTampa$895K
- Ashraf HannaClearwater$608K
- Peter MichaelCoral Gables$496K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.